Roche pays Alector $100M upfront for Parkinson's drug deal

· Health · Switzerland · United States

Roche will pay Alector $100 million upfront in a deal centered on the biotech's neuroscience and Parkinson's disease work. The partnership comes just after the collapse of a separate Alector collaboration, and it is the second large-pharma tie-up announced in the same period. BioPharma Dive grouped the deal with CSL's licensing agreement and the FDA's endorsement of broader use of a Lilly medicine as signs of renewed dealmaking in brain and immune diseases.

Why it matters：Big pharma's renewed appetite for neuroscience deals could revive funding for Parkinson's programs after years of setbacks.

Key points

  • Roche will pay Alector $100 million upfront.
  • The deal focuses on neuroscience and Parkinson's disease.
  • It follows the collapse of a separate Alector partnership.

Sources (original reporting)

More stories from this day